Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Key Resource Suppliers to Be Fined for False Reporting: Draft Economic Security Bill
February 17, 2022
- MHLW Flags Xevudy Supply Disruption, Calls for Use of Other COVID-19 Drugs
February 17, 2022
- MHLW Calls for Considering Veklury Use as Tight Supply Expected for Xevudy
February 16, 2022
- Lawmakers Mixed on Use of Conditional Approval for Shionogi’s COVID-19 Pill
February 16, 2022
- Japan Approves Slew of Generics towards June Listing; Samsca, Xarelto AGs Too
February 16, 2022
- Japan Snags 10 Million Extra Doses of Pfizer Vaccine
February 15, 2022
- Japan Panel OKs Free COVID-19 Vaccination for Ages 5-11, but No “Effort” Obligation Applied
February 14, 2022
- MHLW Panel to Review Bayer’s CKD Drug Finerenone Again on Feb. 25
February 14, 2022
- Pfizer’s Paxlovid Contraindicated with Many Medicines, Requires Careful Use
February 14, 2022
- Japan Approves Pfizer’s Paxlovid, Second Oral COVID-19 Pill
February 10, 2022
- LDP Health Committee to Review PMD Law Amendment Bill Mid-February
February 10, 2022
- Chuikyo Issues 2022 Reform Recommendation; Patch Prescription Limit Lowered to 63 Sheets
February 10, 2022
- Conditional OK Might Be an Option for KM Biologics Jab: Komeito Lawmaker
February 9, 2022
- MHLW to Consider Conditional Approval for Shionogi COVID Pill: Minister
February 9, 2022
- MHLW Ordered Label Revisions for Emergency Contraceptive Levonorgestrel
February 8, 2022
- Japan Mulls Early Conditional Approval for Shionogi’s COVID Pill
February 8, 2022
- Japan to Speed Up Boosters to “1 Million Doses per Day” ASAP: PM
February 7, 2022
- Lilly’s Retevmo Clears PAFSC for Thyroid Cancer; Lenvima/Keytruda to Get RCC Indication
February 7, 2022
- Japan Receiving 90,000 Further Courses of MSD COVID-19 Pill Earlier than Scheduled
February 7, 2022
- FY2022 Drug Price Revision Rate at -6.69% on Pharma Spending Basis
February 4, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…